A multicentre, open-label, phase 3 study to evaluate the efficacy, safety, and pharmacokinetics of emicizumab prophylaxis administered every 4 weeks in persons with haemophilia A - Pipe, S; Shima, M; Lehle, M (Lancet Haematol, 2019)
, et al.